Comparative Pharmacology
Head-to-head clinical analysis: DIURIL versus HYGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIURIL versus HYGROTON.
DIURIL vs HYGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the sodium-chloride symporter, leading to increased excretion of sodium, chloride, and water.
Inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive sodium-chloride cotransporter (NCC), leading to increased excretion of sodium, chloride, and water.
Adults: 500 mg to 1000 mg orally once or twice daily; maximum 2000 mg per day.
25-50 mg orally once daily; may increase to 100 mg once daily for resistant hypertension or edema. Maximum dose 100 mg/day.
None Documented
None Documented
Terminal elimination half-life is 6-15 hours (mean 10 hours). In renal impairment, half-life can exceed 24 hours.
Terminal elimination half-life is approximately 40-50 hours, extending up to 70 hours in patients with renal impairment, allowing for once-daily dosing.
Primarily renal (90-95% excreted unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Renal (approximately 50-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for a minor fraction, less than 10%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic